Helping You Build Wealth With Honest Research
Since 1996. Read On...

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Panacea Biotech Gains 5%; BSE HEALTHCARE Index Up 0.3%
Tue, 5 Nov 9:31

Panacea Biotech Gains 5%; BSE HEALTHCARE Index Up 0.3%Image source: Chunumunu/www.istockphoto.com

Panacea Biotech share price has zoomed 5% and is presently trading at Rs 380.4.

Meanwhile, the BSE HEALTHCARE index is at 43,973.8 (up 0.3%).

Among the top gainers in the BSE HEALTHCARE index today are Procter & Gamble Health (up 6.6%) and GLAND PHARMA (up 3.4%).

FORTIS HEALTHCARE (down 2.4%) and MAX HEALTHCARE INSTITUTE (down 1.9%) are among the top losers today.

Over the last one year, Panacea Biotech has moved up from Rs 149.5 to Rs 380.4, registering a gain of Rs 230.9 (up 154.5%).

On the other hand, the BSE HEALTHCARE index has moved up from 27,350.0 to 43,973.8, registering a gain of 60.8% during the last 12 months.

The top gainers among the BSE HEALTHCARE index stocks during this same period were Jubilant Pharmova (up 229.2%), SUVEN PHARMACEUTICALS (up 130.2%) and Glenmark Pharma (up 129.8%).

Dear Reader: If You Invest in Midcap Stocks, this is for You

What About the Benchmark Indices?

The BSE Sensex is at 78,791.1 .

The top gainers among the BSE Sensex today are JSW Steel (up 1.9%) and Tata Steel (up 1.6%). The most traded stocks in the BSE Sensex are Tata Steel and Tata Motors.

In the meantime, NSE Nifty is at 23,983.7 (down 0.1%). Coal India and MUNDRA PORT & SEZ are among the top losers in NSE NIFTY.

Over the last 12 months, the BSE Sensex has moved up from 63,591.3 to 78,791.1, registering a gain of 15,199.8 points (up 23.9%).

Panacea Biotech Financial Update...

Panacea Biotech net profit fell 244.6% YoY to Rs -159 million for the quarter ended June 2024, compared to a profit of Rs 110 million a year ago. Net sales declined 10.4% to Rs 1,157 million during the period as against Rs 1,292 million in April-June 2023.

For the year ended March 2024, Panacea Biotech reported 95.5% increase in net profit to Rs -15 million compared to net loss of Rs 337 million during FY23. Revenue of the company grew 21.6% to Rs 5,592 million during FY24.

The current Price to earnings ratio of Panacea Biotech, based on rolling 12 month earnings, stands at -82.1.


Equitymaster requests your view! Post a comment on "Panacea Biotech Gains 5%; BSE HEALTHCARE Index Up 0.3%". Click here!